The Isotope Production Map 2026
Q2 2026
The definitive map of the global radiopharmaceutical isotope supply chain. Facility-level production data, supply sufficiency verdicts, and strategic intelligence across 38 radiopharmaceutical isotopes. Written for the operator, investor, or executive who needs to understand not just what is being produced, but what can go wrong, where the hidden dependencies lie, and which announced capacity will actually arrive on schedule.
Authored by
Byron Fitzgerald, Founder, ProGen Search
What This Report Covers
Maps the global radiopharmaceutical isotope supply chain with facility-level precision across 38 isotopes and four production categories. Every supply sufficiency verdict, facility tracker, and fragility assessment reflects the state of play as of Q2 2026. Where claims could not be independently verified, we say so. Where timelines are likely to slip, we explain why.
Constructed through a multi-layered research methodology. Each section was subjected to independent deep-research sweeps across regulatory filings, government budget documents, company disclosures, SEC filings, clinical trial registries, nuclear industry databases, and proprietary intelligence networks. Research outputs were then subjected to structured cross-verification against primary sources, with every material numerical claim independently triangulated. A final analytical synthesis was conducted across the full isotope landscape to identify cross-cutting patterns, correlated fragility clusters, and strategic implications that single-isotope analysis routinely misses.
Buy this report
From
$1,495
Three licence tiers for individuals, teams, and institutions.
Individual
Single reader
$1,495
Enterprise
One operating company
$5,995
Investor & Bank Licence
Banks and institutional investors
$14,995
Chapters
Executive Summary
Five strategic findings cutting across the isotope landscape. Supply sufficiency dashboard, fragility clusters, and the framing for capital allocation, supply chain architecture, and programme risk.
Reactor-Produced Isotopes
Mo-99/Tc-99m, Lu-177, I-131, Ho-166, Sm-153, Sr-89, P-32, Re-186/188, Y-90. Facility trackers, ageing reactor timelines, the PALLAS transition, Darlington CANDU production, SHINE Chrysalis FOAK risk.
Alpha-Emitter Isotopes
Ac-225, Pb-212, Ra-223, Ra-224, Th-227, Bi-213, Bi-212, At-211. The Ac-225 supply gap (2 Ci/year against 50 to 100 Ci/year demand per therapy), the Th-229 monopoly, the Pb-212 distributed manufacturing model, and the Bayer HFIR-bound Xofigo pipeline.
Cyclotron and Accelerator-Produced Isotopes
Cu-64/Cu-67 matched theranostic pair, Tb-161 as Lu-177 successor, F-18, Ga-68, Sc-44/47, Tb-149, Zr-89, I-123/124, C-11. Why short half-lives force decentralised networks, and how the Telix 31-site RLS acquisition reshapes the 1,200-cyclotron global landscape.
Generator Systems
Tc-99m/Mo-99, Ga-68/Ge-68, Rb-82/Sr-82, Pb-212/Ra-224. From the highest-volume diagnostic system in the world to the most structurally novel therapeutic architecture in pharmaceutical history.
Precursor and Feedstock Supply
Ra-226, Th-229, Th-232, Yb-176, Gd-160, Ge-68, Sr-82. The grandparent supremacy thesis: target material is the binding constraint. The structural break in 95 percent Russian Yb-176 dependency through Kinectrics, ASP Isotopes, and the DOE SIPRC at Oak Ridge.
Cross-Cutting Synthesis
Consolidated supply sufficiency table. Five correlated fragility clusters where single infrastructure failures cascade across unrelated programmes: the HFIR Actinide Cascade, the Ageing Reactor Fission Trap, and three more. The zero-sum flux war and the impurity tax that will stratify the market.
The Four-Year Outlook, 2027-2030
2027 the commissioning year, 2028 the alpha pressure year, 2029 the scale-up year, 2030 the transition year. Seven early-warning indicators readers should monitor.
Methodology
Multi-layered research methodology: regulatory filings, government budget documents, company disclosures, clinical registries, nuclear industry databases, structured cross-verification, and analytical synthesis across the full isotope landscape.
Disclaimer & Sources
Limitations of forward-looking statements. Sources spanning DOE, NRC, IAEA, OECD-NEA, SEC filings, peer-reviewed journals, and proprietary intelligence.
From the report
$9B+
in Big Pharma M&A flowed into radiopharmaceutical isotopes across four 2023-2024 transactions.
The supply chain underneath it depends on five research reactors commissioned before the Moon landing.
Who reads this and what they use it for
Isotope and radiopharma operators
CEOs, COOs, CSOs, and VP-level leaders at isotope production companies, radiopharmaceutical developers, and CDMOs evaluating capacity, fragility, and competitive position.
Investors and corporate development
PE and VC firms plus corporate development teams at large pharma, evaluating radiopharma infrastructure for due diligence, valuation, and acquisition theses.
Hospital and procurement leadership
Hospital nuclear medicine directors and procurement teams using the isotope-level facility trackers and supply verdicts as reference data for sourcing decisions.
Byron Fitzgerald, Founder, ProGen Search
About the Author
Byron Fitzgerald
Byron Fitzgerald has spent more than 15 years in life sciences executive search and founded ProGen Search in 2024. He is a three-time founder, having previously bootstrapped a specialist consultancy from a standing start to 36 consultants. He has placed VP to C-suite leadership across Quality, MSAT, Technical Operations, CMC, Manufacturing, Regulatory, and Business Development functions for organisations ranging from pre-clinical biotechs to multinational CDMOs and radiopharma developers. Through retained search and commissioned intelligence work, he speaks daily with the C-suite, investors, PE/VC partners, and BD leaders who set strategy across this sector.
His published market intelligence on radiopharmaceutical manufacturing, CDMO capacity constraints, ADC execution risk, and advanced modality talent markets is read by C-suite leaders, institutional investors, and board members globally.
Choose your access
Three tiers, calibrated to how you intend to use the work.
Individual
$1,495
Single reader. Personal use within one company.
- Single named reader licence
- Full PDF report (56 pages, all 10 exhibits)
- Source attribution for internal slide decks and memos: "Source: ProGen Search Limited" or "Source: ProGen Search"
- Direct email access to Byron Fitzgerald for clarification questions
Enterprise
$5,995
Distribute across one operating company or strategy team.
- Full company licence covering all employees and majority-owned subsidiaries
- Full PDF report (56 pages, all 10 exhibits)
- Internal redistribution rights (intranet, shared drives, board packs)
- Source attribution required when used in client-facing or external materials: "Source: ProGen Search Limited" or "Source: ProGen Search"
- Priority email access to Byron Fitzgerald
Investor & Bank Licence
$14,995
Investment banks, institutional investors, and consulting firms citing the report in client materials.
- Full firm licence covering all investment professionals, analysts, and portfolio companies
- Full PDF report (56 pages, all 10 exhibits)
- Use in investor memos, client deliverables, due diligence reports, and committee papers
- Source attribution required: "Source: ProGen Search Limited" or "Source: ProGen Search"
- Priority email access to Byron Fitzgerald
By completing your purchase, you agree to our Purchase Terms.
Frequently asked questions
How is this different from State of Radiopharmaceuticals 2026?
State of Radiopharmaceuticals 2026 maps the clinical and commercial landscape: which drugs are in development, who owns them, and where the M&A is flowing. The Isotope Production Map sits one layer beneath that. It maps the physical infrastructure that has to deliver the atoms before any of those drugs can reach a patient. Reactor by reactor, cyclotron by cyclotron, precursor by precursor. Reading them together gives you the full picture from molecule to manufacturing.
How current is the data?
All facility statuses, regulatory decisions, and commercial agreements reflect Q2 2026. Where claims could not be independently verified, we say so. Where timelines are likely to slip, we explain why. The earliest events referenced span 2024 to 2026.
What numerical claims are independently verified versus modelled?
Facility commissioning dates, regulatory filings, and announced capacities trace to primary sources (DOE Isotope Program, NRC filings, CNSC licences, company press releases, SEC disclosures). Patient volume estimates and market size projections derive from third-party industry research sources whose underlying methodologies are not publicly disclosed; these are clearly labelled in context.
Can I share this with my team or board?
The Individual Licence covers a single named reader. The Enterprise Licence covers your full organisation, including subsidiaries. The Investor & Bank Licence extends that scope to your portfolio companies and clients. See the Purchase Terms for the precise scope of each tier.
Ready when you are.
If your team is making radiopharma capital, sourcing, or strategy decisions this year, the isotope supply chain is where the binding constraints live. This report is the operating manual.
View pricing